Interactions between Myc and inflammatory mediators in chronic liver disease

Author(s): Yang Heping

Most Chronic Liver Diseases (CLDs) are characterized by inflammatory processes with abnormal expression of various pro- and anti-inflammatory mediators in the liver. These mediators are the driving force behind many inflammatory disorders of the liver, often leading to fibrosis, cirrhosis, and liver tumorigenesis. c-Myc is involved in many cellular events such as cell growth, proliferation, and differentiation. c-Myc upregulates IL-8, IL-10, TNF-α and TGF-β, while IL-1, IL-2, IL-4, TNF-α and TGF-β promote the expression of c-Myc. Their interaction plays a central role in fibrosis, cirrhosis, and liver cancer. The molecular interference of their interactions offers a possible therapeutic potential for CLD. In this review, current knowledge on the molecular interactions between c-Myc and various well-known inflammatory mediators will be discussed. Chronic Liver Disease (CLD) is a major cause of morbidity and mortality worldwide. Furthermore, the burden of LTC is expected to increase. Inflammatory cytokines are a group of important regulatory mediators involved in the development of CLD. The development and progression of CLD has been associated with hepatitis B, hepatitis C, alcoholic liver disease, drug-induced liver disease, autoimmune liver disease, Hepato Cellular Carcinoma (HCC), and Cholangio Carcinoma (CCA).